Japanese Journal of Clinical Oncology 31:69-73 (2001)
© 2001 Foundation for Promotion of Cancer Research
Altretamine is an Effective Palliative Therapy of Patients with Recurrent Epithelial Ovarian Cancer
Department of Medical Oncology, National Cancer Institute, Karachi, Pakistan
Background: Management of patients with recurrent epithelial ovarian cancer is difficult. Although several agents are active, responses are short-lived and observed in only a small number of patients. Side effects of these drugs are substantial. There is a need for more effective and less toxic therapies. Altretamine is a well tolerated oral agent with minimal toxicity. There are only a few trials evaluating its efficacy as a single agent in recurrent epithelial ovarian cancer.
Methods: We prospectively studied patients with recurrent epithelial ovarian cancer who were able to take oral medication and had adequate bone marrow, liver and renal functions. All had been previously treated with at least one platinum-based chemotherapy regimen and had either relapsed or failed to achieve an adequate response.
Results: Seventeen patients were studied. The commonest histological subtype was serous adenocarcinoma. Seven patients had platinum refractory disease. The mean duration of therapy was 6.1 months. Six patients (35%) achieved complete or partial remission, time to progression was 6.0 months and mean overall survival was 15.1 months. Toxicity was primarily nausea, vomiting and asthenia and was easily manageable.
Conclusion: Altretamine is an acceptable and apparently less toxic alternative to other cytotoxic drugs used for palliation of patients with recurrent epithelial ovarian cancer.
+ For reprints and all correspondence: Imtiaz A. Malik, University of Cincinnati – Barrett Cancer Center, 234 Goodman Street, Cincinnati, OH 45267–0501, USA. E-mail: malikia@ucmail.uc.edu